Related Experiment Video

Updated: May 28, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

The triple-negative subtype: new ideas for the poorest prognosis breast cancer

Giuseppe Curigliano1, Aron Goldhirsch

  • 1Department of Medicine, Division of Medical Oncology, Istituto Europeo di Oncologia, Milano 20141, Italy. giuseppe.curigliano@ieo.it

Journal of the National Cancer Institute. Monographs
|November 2, 2011
PubMed

Insights

Triple-negative breast cancer (TNBC) has a high relapse risk. Cisplatin chemotherapy and targeted therapies like PARP inhibitors show promise for TNBC treatment, especially in BRCA1-mutated cases.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) comprises 15-20% of breast cancers.
  • TNBC patients face elevated risks of mortality and disease recurrence.
  • Specific molecular aberrations, including p53 mutations and BRCA1 dysfunction, characterize TNBC.

Purpose of the Study:

  • To review current therapeutic strategies for triple-negative breast cancer.
  • To explore the efficacy of chemotherapy and emerging targeted therapies.
  • To identify potential advancements in TNBC management.

Main Methods:

  • Literature review of studies on triple-negative breast cancer treatments.
  • Analysis of data on DNA alkylating agents (e.g., cisplatin) in neoadjuvant settings.
  • Evaluation of targeted therapies, including Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors.

Main Results:

  • Cisplatin demonstrates effectiveness in the neoadjuvant treatment of TNBC.
  • PARP-1 inhibitors show single-agent activity in BRCA1-mutated breast cancer.
  • PARP-1 inhibitors may enhance cisplatin sensitivity in TNBC.

Conclusions:

  • Chemotherapy remains a fundamental treatment for TNBC.
  • Integrating targeted agents with chemotherapy in biology-driven trials may improve outcomes.
  • Further research is needed to optimize TNBC patient management.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...